Active Ingredient History
CMX157 is a lipid (1-0-hexadecyloxypropyl) conjugate of the acyclic nucleotide analog tenofovir (TFV) with activity against both wild-type and antiretroviral drug-resistant HIV strains, including multidrug nucleoside/nucleotide analog-resistant viruses. CMX157 was designed to mimic lysophosphatidylcholine to take advantage of natural lipid uptake pathways and to achieve high intracellular concentrations of the active antiviral, with the aim of increasing the effectiveness of TFV against wild-type and mutant HIV. CMX157 demonstrated potential to effectively suppress replication of multiNRTI-resistant (MNR) HIV that cannot be treated with any currently available NRTIs, including TDF. It is in phase II clinical trial for HIV infections in USA and phase Ib portion of the phase I/II trial for Hepatitis B in Thailand (PO). NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acquired Immunodeficiency Syndrome (Phase 4)
Acute-On-Chronic Liver Failure (Phase 4)
Aicardi Syndrome (Phase 2)
AIDS-Related Opportunistic Infections (Phase 4)
Alcohol-Induced Disorders (Phase 4)
Alveolar Bone Loss (Phase 4)
Amphetamine-Related Disorders (Phase 2)
Analgesics, Opioid (Phase 4)
Anesthesia (Phase 4)
Anti-Infective Agents (Phase 1)
Anti-Retroviral Agents (Phase 2)
Antiretroviral Therapy, Highly Active (Phase 4)
Atazanavir Sulfate (Phase 1)
Atherosclerosis (Phase 2)
Behavior and Behavior Mechanisms (Phase 1/Phase 2)
Bone Diseases (Phase 4)
Bone Diseases, Metabolic (Phase 4)
Breast Feeding (Phase 3)
Carcinoma, Hepatocellular (Phase 4)
Cardiovascular Diseases (Phase 4)
Central Nervous System (Phase 2)
Central Nervous System Diseases (Phase 4)
Cognition Disorders (Phase 4)
Communicable Diseases (Phase 2)
Congenital Abnormalities (Phase 4)
Contraception (Phase 2)
Contraception Behavior (Phase 1)
Coronavirus Infections (Phase 3)
COVID-19 (Phase 3)
Dementia (Phase 4)
Depression (Phase 4)
Drug Interactions (Phase 1)
Drug Misuse (Phase 1)
Drugs, Investigational (Phase 4)
Dyslipidemias (Phase 4)
Estrogens (Phase 4)
Fibrosis (Phase 4)
Gender Dysphoria (Phase 1)
Gender Identity (Phase 1/Phase 2)
Healthy Volunteers (Phase 4)
Hepacivirus (Phase 1)
Hepatitis (Phase 1)
Hepatitis B (Phase 4)
Hepatitis B virus (Phase 3)
Hepatitis C (Phase 4)
Hepatitis C, Chronic (Phase 3)
Hepatitis, Chronic (Phase 4)
Hepatitis D (Phase 2)
Hepatitis D, Chronic (Phase 3)
Herpes Genitalis (Phase 4)
HIV (Phase 4)
HIV-1 (Phase 4)
HIV-Associated Lipodystrophy Syndrome (Phase 4)
HIV Seronegativity (Phase 2/Phase 3)
HIV Seropositivity (Phase 2)
Hormones (Phase 4)
Infections ()
Insulin Resistance (Phase 1)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 1)
Lipodystrophy (Phase 2)
Liver Cirrhosis (Phase 4)
Liver Cirrhosis, Biliary (Phase 2)
Liver Diseases (Phase 1)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 3)
Lymphoma, Non-Hodgkin (Phase 4)
Malaria (Phase 3)
Medication Adherence (Phase 4)
Menopause (Phase 4)
Metabolic Diseases (Phase 4)
Mitochondrial Diseases (Phase 2)
Nutrition Disorders (Phase 2)
Obesity (Phase 4)
Opioid-Related Disorders (Phase 4)
Organ Transplantation (Phase 4)
Osteoporosis (Phase 4)
Parasitic Diseases (Phase 2)
Patient Compliance (Phase 4)
Persistent Infection (Phase 4)
Pharmacokinetics (Phase 1)
Pre-Exposure Prophylaxis (Phase 4)
Pregnancy (Phase 4)
Proteinuria (Phase 4)
Quality of Life (Phase 4)
Rectum (Phase 1)
Renal Insufficiency (Phase 4)
Respiratory Tract Infections (Phase 1/Phase 2)
Risk Factors (Phase 1)
Risk Reduction Behavior (Phase 4)
Risk-Taking (Phase 4)
Sarcoma, Kaposi (Phase 4)
SARS-CoV-2 (Phase 2/Phase 3)
Sexual Behavior (Phase 4)
Sexually Transmitted Diseases (Phase 4)
Sleep Disorders, Intrinsic (Phase 4)
Sleep Wake Disorders (Phase 4)
Substance Abuse, Oral (Phase 2)
Substance-Related Disorders (Phase 4)
Syphilis (Phase 4)
Tenofovir (Phase 4)
Transgender Persons (Phase 4)
Tuberculosis (Phase 4)
Vascular Diseases (Phase 2)
Viremia (Phase 4)
Weight Gain (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
